{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:09:00Z","timestamp":1761512940389},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) is a provisional entity in the current World Health Organization classification and is thought to be a myelodysplastic\/myeloproliferative neoplasm (MDS\/MPN). We analyzed 18 cases of RARS-T. All patients had thrombocytosis (platelet count, 515\u20131,100 \u00d7 103\/\u03bcL [515\u20131,100 \u00d7 109\/L]) and anemia (hemoglobin level, 7.2\u201312.6 g\/dL [72\u2013126 g\/L]). Three patients had mild leukocytosis (WBC count, 3,900\u201316,300\/\u03bcL [3.9\u201316.3 \u00d7 109\/L]). Ring sideroblasts were 8% to 75% in the bone marrow. Megakaryocytes showed a spectrum of morphologic findings. JAK2V617F was identified in 9 of 15 cases, including 7 of 9 with thrombocytosis (platelet count, &amp;gt;600 \u00d7 103\/\u03bcL [600 \u00d7 109\/L]) and 1 with 8% ring sideroblasts. The MPLW515L mutation was not detected (n = 9). We conclude that RARS-T is a pathogenetically heterogeneous group of limited diagnostic usefulness. Approximately 60% of cases carry JAK2V617Fand seem to be closer to an MPN in which ring sideroblasts may be a secondary phenomenon. The remaining cases usually lack the JAK2V617Fmutation, have a platelet count less than 600 \u00d7 103\/\u03bcL (600 \u00d7 109\/L), and may represent an MDS or MPN with thrombocytosis of unknown mechanisms.<\/jats:p>","DOI":"10.1309\/ajcpt0b6veqprcoa","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T18:37:47Z","timestamp":1298572667000},"page":"398-403","source":"Crossref","is-referenced-by-count":16,"title":["Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis"],"prefix":"10.1093","volume":"135","author":[{"given":"Inga","family":"Gurevich","sequence":"first","affiliation":[{"name":"Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergej N.","family":"Konoplev","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Cameron","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"key":"2023011909493406600_b1-1350398","first-page":"85","article-title":"Myelodysplastic\/myeloproliferative neoplasm, unclassifiable","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Vardiman","year":"2008","edition":"4th ed"},{"key":"2023011909493406600_b2-1350398","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2006-02-005751","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation","volume":"108","author":"Szpurka","year":"2006","journal-title":"Blood"},{"key":"2023011909493406600_b3-1350398","first-page":"719","article-title":"Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic\/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"91","author":"Remacha","year":"2006","journal-title":"Haematologica"},{"key":"2023011909493406600_b4-1350398","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.leu.2404316","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features","volume":"20","author":"Wang","year":"2006","journal-title":"Leukemia"},{"key":"2023011909493406600_b5-1350398","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2006-03-008227","article-title":"The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS) [letter]","volume":"108","author":"Boissinot","year":"2006","journal-title":"Blood"},{"key":"2023011909493406600_b6-1350398","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.leu.2404373","article-title":"The JAK2 V617F mutation is rare in RARS but common in RARS-T [letter]","volume":"20","author":"Ceesay","year":"2006","journal-title":"Leukemia"},{"key":"2023011909493406600_b7-1350398","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404405","article-title":"High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"20","author":"Renneville","year":"2006","journal-title":"Leukemia"},{"key":"2023011909493406600_b8-1350398","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2006-05-022491","article-title":"High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count &gt;600 \u00d7 109\/L) and ringed sideroblasts more than 15% considered as MDS\/MPD, unclassifiable","volume":"109","author":"Gattermann","year":"2007","journal-title":"Blood"},{"key":"2023011909493406600_b9-1350398","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.leu.2404909","article-title":"Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis","volume":"22","author":"Schnittger","year":"2008","journal-title":"Leukemia"},{"key":"2023011909493406600_b10-1350398","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"2023011909493406600_b11-1350398","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/modpathol.2008.92","article-title":"Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations","volume":"21","author":"Lin","year":"2008","journal-title":"Mod Pathol"},{"key":"2023011909493406600_b12-1350398","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.humpath.2009.11.004","article-title":"JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome","volume":"41","author":"Lin","year":"2010","journal-title":"Hum Pathol"},{"key":"2023011909493406600_b13-1350398","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2009.10.014","article-title":"Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations","volume":"197","author":"Millecker","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"2023011909493406600_b14-1350398","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2023011909493406600_b15-1350398","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12185-008-0169-1","article-title":"Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status","volume":"88","author":"Raya","year":"2008","journal-title":"Int J Hematol"},{"key":"2023011909493406600_b16-1350398","first-page":"392","article-title":"Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity","volume":"87","author":"Schmitt-Graeff","year":"2002","journal-title":"Haematologica"},{"key":"2023011909493406600_b17-1350398","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.11581","article-title":"JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"93","author":"Schmitt-Graeff","year":"2008","journal-title":"Haematologica"},{"key":"2023011909493406600_b18-1350398","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.leukres.2009.08.019","article-title":"Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with chromosomal evolution including monosomy 7 [letter]","volume":"34","author":"Pich","year":"2010","journal-title":"Leuk Res"},{"key":"2023011909493406600_b19-1350398","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"2023011909493406600_b20-1350398","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/leu.2008.229","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science","volume":"22","author":"Kilpivaara","year":"2008","journal-title":"Leukemia"},{"key":"2023011909493406600_b21-1350398","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2023011909493406600_b22-1350398","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","article-title":"Molecular aspects of myeloproliferative neoplasms","volume":"91","author":"Delhommeau","year":"2010","journal-title":"Int J Hematol"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/135\/3\/398\/48769840\/ajcp_135_3_398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/135\/3\/398\/48769840\/ajcp_135_3_398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T11:32:56Z","timestamp":1674127976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/135\/3\/398\/1766242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,3,1]]},"published-print":{"date-parts":[[2011,3,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcpt0b6veqprcoa","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,3,1]]},"published":{"date-parts":[[2011,3,1]]}}}